The Center for Psychedelic Research and Therapy at The University of Texas at Austin Dell Medical School is currently seeking individuals to participate in a paid research study that examines brain responses and how they may be altered following a course of treatment including psilocybin or 5-methoxydimethyltryptamine (5-MeO DMT) along with psychotherapy in bereaved spouses, significant others, or family members.
We hope to learn more about how brain function is influenced by psychedelic assisted therapy and how this may impact psychiatric symptoms related to the loss of a loved one. family of military service members are prone to experiencing symptoms of complicated grief/prolonged grief disorder, particularly because military-related deaths often occur suddenly and without warning.
You may qualify for this study if you are:
Transportation and hotels at Austin will be covered, as will incidental expenses for meals and ground transportation.If you are interested in more information, please contact us, or consent to allowing us to contact you!
Individuals can earn up to $925 for participation in this study and will additionally be provided two all-expenses paid trips to beautiful Austin, TX! You could also be reimbursed to hire a caregiver in your absence if you meet certain requirements. This is a prime opportunity to contribute to providing better mental health treatment to bereaved romantic partners or family members of military service members.
The study will test the hypothesis that the receipt of psilocybin or 5-MeO-DMT assisted psychotherapy will: (1) demonstrate therapeutic benefits for mental health symptoms of prolonged/complicated grief, depression, and posttraumatic stress symptoms; and (2) promote changes in brain function that show relationships to facets of clinical symptom change.
This study will measure changes in brain function utilizing functional magnetic resonance imaging (fMRI) and electroencephalographic recordings (EEG) that occur before and after participating in a retreat. Additional tests and measures will be performed.
1. Evidence of the current or prior history of psychosis or bipolar disorder as evidenced by self-report or clinical interview.
2. Unremovable ferrous metal in the body.
3. History of neurological disorder, stroke, seizures/convulsions (except febrile seizures in childhood), epilepsy, brain surgery, electroconvulsive or radiation treatment, brain hemorrhage or tumor, moderate-to-severe head injury or any penetrating head injury, or an uncontrolled thyroid disorder.
4. Current psychological and/or physical conditions that would be contraindicated for treatment with psilocybin or 5-MeO DMT, including, but not limited to, uncontrolled hypertension, cardiac arrhythmias, the taking of certain medications known to be contraindicated for use with serotonergic psychedelics (e.g., monoamine oxidase inhibitors), current active alcohol or drug dependence, and being pregnant or about to become pregnant.